Annex 3: Summary of Performance Assessment by Objectives as of March 2015 Validation of Results Result measurements Performance: achievements Key remaining issues/ challenges assumptions/ risk Preservation of the effectiveness of Artemisinin Combination Therapies by containing and ultimately eliminating artemisinin resistant P. falciparum Project goal: malaria parasites in the Greater Mekong Subregion Artemisinin Confirmed or suspected Project on except for Need to translate the developed Risks: resistance does not resistance (as defined by WHO) Objective 6 and partly Objective 3. strategies, plans and tools into Reduced funding spread beyond the has not been detected in Progress in relation to Objectives interventions targeting beneficiaries at from national budgets GMS. therapeutic efficacy studies (TES) 2 and 4, as core business of regional and national levels. (and traditional conducted outside the GMS. WHO, has been more rapid than Decreased malaria National ownership likely to be critical donors) given the (Source: TES reports) progress in relation to other burden in the GMS. for successful achievement of the decline in malaria objectives. Falling prevalence/ incidence of project goal. cases in most GMS confirmed falciparum malaria Project has caught up with the affected countries. WHO’s technical coordination and cases in every country in the pace and recent dynamics of support likely to be critical. This is Wider emergence of GMS. (Source: survey and malaria elimination in the region. because of differing stages of malaria artemisinin resistance surveillance data) Contributed to enhancing containment/elimination, resources and multi-drug awareness of ERAR and available, levels of commitments, and resistance. maintaining regional momentum priorities of the affected countries and for AR and malaria. increased dynamics in regional integration. WHO’s technical Strategic products and activities and support should be in provide a regional foundation to areas of WHO’s core business. support the GMS countries to transit to malaria elimination. WHO has continued monitoring prevalence/incidence of confirmed Falciparum malaria cases in GMS through survey and surveillance. Suspected resistance outside the GMS are continued monitoring through TES.
Annex 3: Summary of Performance Assessment by Objectives as of March 2015 Results Result measurements Performance: achievements Key remaining issues/ challenges Validation of assumptions/ risk Project goal: Preservation of the effectiveness of Artemisinin Combination Therapies by containing and ultimately eliminating artemisinin resistant P. falciparum malaria parasites in the Greater Mekong Subregion Artemisinin resistance does not spread beyond the GMS. Decreased malaria burden in the GMS. Confirmed or suspected resistance (as defined by WHO) has not been detected in therapeutic efficacy studies (TES) conducted outside the GMS. (Source: TES reports) Falling prevalence/ incidence of confirmed falciparum malaria cases in every country in the GMS. (Source: survey and surveillance data) Project on except for Objective 6 and partly Objective 3. Progress in relation to Objectives 2 and 4, as core business of WHO, has been more rapid than progress in relation to other objectives. Project has caught up with the pace and recent dynamics of malaria elimination in the region. Contributed to enhancing awareness of ERAR and maintaining regional momentum for AR and malaria. Strategic products and activities provide a regional foundation to support the GMS countries to transit to malaria elimination. WHO has continued monitoring prevalence/incidence of confirmed Falciparum malaria cases in GMS through survey and surveillance. Suspected resistance outside the GMS are continued monitoring through TES. Need to translate the developed strategies, plans and tools into interventions targeting beneficiaries at regional and national levels. National ownership likely to be critical for successful achievement of the project goal. WHO’s technical coordination and support likely to be critical. This is because of differing stages of malaria containment/elimination, resources available, levels of commitments, and priorities of the affected countries and increased dynamics in regional integration. WHO’s technical and support should be in areas of WHO’s core business. Risks: Reduced funding from national budgets (and traditional donors) given the decline in malaria cases in most GMS affected countries. Wider emergence of artemisinin resistance and multi-drug resistance.
coordination-of-the-emergency-response-to-artemisinin-resistance-independent-mid-term-review.docx